Key Points
- Insider sales: Director Reuven Yeganeh sold 450,000 shares on March 16 for $5.00 each ($2.25M) and 530,000 shares on March 17 for $5.00 each ($2.65M), totaling 980,000 shares worth about $4.9M.
- BiomX shares were down 3.6%, trade near a market cap of $8.01 million with a 50-day moving average below the 200-day (4.92 vs. 6.35), and HC Wainwright recently downgraded the stock to a "hold" from "buy" (consensus rating: Hold).
- BiomX is a clinical-stage biotech developing precision bacteriophage therapies for gastrointestinal and dermatological indications, and institutional investors own roughly 40.6% of the company (Citadel reported a small new stake).
BiomX Inc. (NYSEAMERICAN:PHGE - Get Free Report) Director Reuven Yeganeh sold 450,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $5.00, for a total value of $2,250,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Reuven Yeganeh also recently made the following trade(s):
- On Tuesday, March 17th, Reuven Yeganeh sold 530,000 shares of BiomX stock. The shares were sold at an average price of $5.00, for a total transaction of $2,650,000.00.
BiomX Stock Down 3.6%
BiomX stock opened at $5.04 on Thursday. The company has a 50 day moving average of $4.92 and a 200-day moving average of $6.35. BiomX Inc. has a twelve month low of $1.50 and a twelve month high of $14.71. The stock has a market capitalization of $8.01 million, a PE ratio of -0.20 and a beta of 1.68.
BiomX (NYSEAMERICAN:PHGE - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The company reported $6.99 EPS for the quarter. Equities analysts anticipate that BiomX Inc. will post -2.77 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, HC Wainwright lowered BiomX from a "buy" rating to a "hold" rating in a report on Monday, March 9th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $26.00.
Check Out Our Latest Stock Analysis on PHGE
Hedge Funds Weigh In On BiomX
An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC acquired a new stake in BiomX Inc. (NYSEAMERICAN:PHGE - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 161,781 shares of the company's stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent SEC filing. Institutional investors own 40.57% of the company's stock.
About BiomX
(
Get Free Report)
BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company's platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.
The company's pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
